Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Tamoxifen versus no tamoxifen and phenotype interaction on Ki-67 modulation.

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

Variable Reduced   Active  
  Tamoxifen
Median (Low/upper quartile)
No tamoxifen
Median (Low/upper quartile)
Tamoxifen
Median (Low/upper quartile)
No tamoxifen
Median (Low/upper quartile)
Ki-67 change 2.5 (-2/7) 0 (-5/2) -2.5 (-10/0) 0 (-1/4)